These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 31685558)

  • 1. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
    Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
    Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
    Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
    Kristeleit R; Lisyanskaya A; Fedenko A; Dvorkin M; de Melo AC; Shparyk Y; Rakhmatullina I; Bondarenko I; Colombo N; Svintsitskiy V; Biela L; Nechaeva M; Lorusso D; Scambia G; Cibula D; Póka R; Oaknin A; Safra T; Mackowiak-Matejczyk B; Ma L; Thomas D; Lin KK; McLachlan K; Goble S; Oza AM
    Lancet Oncol; 2022 Apr; 23(4):465-478. PubMed ID: 35298906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA;
    Lancet; 2017 Oct; 390(10106):1949-1961. PubMed ID: 28916367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
    Moore DC; Ringley JT; Patel J
    J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious
    Balasubramaniam S; Beaver JA; Horton S; Fernandes LL; Tang S; Horne HN; Liu J; Liu C; Schrieber SJ; Yu J; Song P; Pierce W; Robertson KJ; Palmby TR; Chiu HJ; Lee EY; Philip R; Schuck R; Charlab R; Banerjee A; Chen XH; Wang X; Goldberg KB; Sridhara R; Kim G; Pazdur R
    Clin Cancer Res; 2017 Dec; 23(23):7165-7170. PubMed ID: 28751443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    Kristeleit RS; Drew Y; Oza AM; Domchek SM; Banerjee S; Glasspool RM; Balmaña J; Chen LM; Patel MR; Burris HA; Safra T; Borrow J; Lin KK; Goble S; Maloney L; Shapira-Frommer R
    Br J Cancer; 2023 Jan; 128(2):255-265. PubMed ID: 36482193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
    Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
    Dal Molin GZ; Westin SN; Coleman RL
    Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
    Steffensen KD; Adimi P; Jakobsen A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
    Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
    Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
    Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
    Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
    Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
    Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.